Flanigan Jessica
Leadership Studies, and Philosophy, Politics, Economics, and Law, University of Richmond, 28 Westhampton Way, Richmond, VA, 23173, USA,
HEC Forum. 2013 Aug 20. doi: 10.1007/s10730-013-9222-4.
I argue that young patients should be able to access neuroenhancing drugs without a diagnosis of ADHD. The current framework of consent for pediatric patients can be adapted to accommodate neuroenhancement. After a brief overview of pediatric neuroenhancement, I develop three arguments in favor of greater acceptance of neuroenhancement for young patients. First, ADHD is not relevantly different from other disadvantages that could be treated with stimulant medication. Second, establishing a legitimate framework for pediatric neuroenhancement would mitigate the bad effects of diversion and improve research on neuroenhancement and ADHD. Third, some pediatric patients have rights to access neuroenhancements. I then consider several objections to pediatric neuroenhancement. I address concerns about addiction, advertising, authentic development, the parent-child relationship and equal opportunity and conclude that these concerns may inform a framework for prescribing neuroenhancement but they do not justify limits on prescribing.
我认为，即使没有被诊断患有注意力缺陷多动障碍（ADHD），年轻患者也应该能够获取神经增强药物。目前针对儿科患者的同意框架可以进行调整，以适应神经增强的需求。在对儿科神经增强进行简要概述之后，我提出了三个论据，支持更广泛地接受对年轻患者使用神经增强药物。第一，ADHD与其他可用兴奋剂药物治疗的不利状况并无实质区别。第二，建立一个合理的儿科神经增强框架将减轻药物滥用的不良影响，并改善对神经增强和ADHD的研究。第三，一些儿科患者有权使用神经增强药物。接着，我考虑了对儿科神经增强的几个反对意见。我讨论了对成瘾、广告宣传、真实发育、亲子关系和平等机会的担忧，并得出结论，这些担忧可能为制定神经增强药物的处方框架提供参考，但它们并不能成为限制处方的理由。
